S&P 500   2,968.44 (-0.06%)
DOW   26,809.34 (-0.03%)
QQQ   191.39 (+0.15%)
AAPL   236.24 (+0.01%)
FB   183.50 (-0.37%)
MSFT   139.89 (+0.15%)
GOOGL   1,220.67 (+0.41%)
AMZN   1,739.59 (+0.44%)
CGC   18.75 (-3.50%)
NVDA   186.48 (+0.26%)
MU   44.87 (-0.51%)
BABA   171.60 (-0.77%)
GE   8.74 (-0.68%)
TSLA   257.17 (+3.74%)
AMD   30.49 (+2.49%)
T   37.46 (-0.32%)
PRI   121.49 (-0.16%)
NFLX   286.50 (+1.26%)
BAC   29.06 (+0.52%)
GILD   64.48 (+0.75%)
DIS   129.77 (-0.19%)
S&P 500   2,968.44 (-0.06%)
DOW   26,809.34 (-0.03%)
QQQ   191.39 (+0.15%)
AAPL   236.24 (+0.01%)
FB   183.50 (-0.37%)
MSFT   139.89 (+0.15%)
GOOGL   1,220.67 (+0.41%)
AMZN   1,739.59 (+0.44%)
CGC   18.75 (-3.50%)
NVDA   186.48 (+0.26%)
MU   44.87 (-0.51%)
BABA   171.60 (-0.77%)
GE   8.74 (-0.68%)
TSLA   257.17 (+3.74%)
AMD   30.49 (+2.49%)
T   37.46 (-0.32%)
PRI   121.49 (-0.16%)
NFLX   286.50 (+1.26%)
BAC   29.06 (+0.52%)
GILD   64.48 (+0.75%)
DIS   129.77 (-0.19%)
Log in

Medpace Stock Price, News & Analysis (NASDAQ:MEDP)

$77.79
-0.95 (-1.21 %)
(As of 10/14/2019 03:05 PM ET)
Today's Range
$77.41
Now: $77.79
$79.32
50-Day Range
$77.68
MA: $82.11
$86.02
52-Week Range
$45.88
Now: $77.79
$86.71
Volume383,595 shs
Average Volume363,388 shs
Market Capitalization$2.79 billion
P/E Ratio30.03
Dividend YieldN/A
Beta1.55
Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas. Read More…

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MEDP
CUSIPN/A
Phone513-579-9911

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$704.59 million
Cash Flow$3.55 per share
Book Value$16.56 per share

Profitability

Net Income$73.18 million

Miscellaneous

Employees2,900
Market Cap$2.79 billion
Next Earnings Date10/28/2019 (Confirmed)
OptionableOptionable

Receive MEDP News and Ratings via Email

Sign-up to receive the latest news and ratings for MEDP and its competitors with MarketBeat's FREE daily newsletter.


Medpace (NASDAQ:MEDP) Frequently Asked Questions

What is Medpace's stock symbol?

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

How were Medpace's earnings last quarter?

Medpace Holdings Inc (NASDAQ:MEDP) posted its quarterly earnings data on Monday, July, 29th. The company reported $0.81 EPS for the quarter, beating the Zacks' consensus estimate of $0.63 by $0.18. The company had revenue of $214.10 million for the quarter, compared to analyst estimates of $200.99 million. Medpace had a net margin of 11.28% and a return on equity of 17.65%. The company's quarterly revenue was up 25.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.61 EPS. View Medpace's Earnings History.

When is Medpace's next earnings date?

Medpace is scheduled to release their next quarterly earnings announcement on Monday, October 28th 2019. View Earnings Estimates for Medpace.

How can I listen to Medpace's earnings call?

Medpace will be holding an earnings conference call on Monday, October 28th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has Medpace issued on next quarter's earnings?

Medpace issued an update on its FY19 earnings guidance on Monday, July, 29th. The company provided EPS guidance of $2.83-2.93 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.65. The company issued revenue guidance of $840-860 million, compared to the consensus revenue estimate of $827.58 million.

What price target have analysts set for MEDP?

4 analysts have issued twelve-month price targets for Medpace's shares. Their forecasts range from $62.00 to $85.00. On average, they anticipate Medpace's stock price to reach $74.67 in the next year. This suggests that the stock has a possible downside of 4.0%. View Analyst Price Targets for Medpace.

What is the consensus analysts' recommendation for Medpace?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Medpace.

Has Medpace been receiving favorable news coverage?

News stories about MEDP stock have trended negative recently, InfoTrie reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Medpace earned a coverage optimism score of -2.8 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Medpace.

Are investors shorting Medpace?

Medpace saw a drop in short interest during the month of September. As of September 15th, there was short interest totalling 2,320,000 shares, a drop of 12.8% from the August 15th total of 2,660,000 shares. Based on an average daily volume of 407,200 shares, the days-to-cover ratio is currently 5.7 days. Currently, 8.5% of the company's stock are short sold. View Medpace's Current Options Chain.

Who are some of Medpace's key competitors?

What other stocks do shareholders of Medpace own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include EXACT Sciences (EXAS), NVIDIA (NVDA), Alibaba Group (BABA), BioTelemetry (BEAT), Paypal (PYPL), Paycom Software (PAYC), Square (SQ), Cisco Systems (CSCO), Intuitive Surgical (ISRG) and ABIOMED (ABMD).

Who are Medpace's key executives?

Medpace's management team includes the folowing people:
  • Dr. August James Troendle, Chairman, Pres & CEO (Age 63)
  • Mr. Jesse J. Geiger, CFO & Chief Operating Officer of Laboratory Operations (Age 45)
  • Ms. Susan E. Burwig, Exec. VP of Operations (Age 56)
  • Mr. Stephen P. Ewald, Gen. Counsel & Corp. Sec. (Age 50)
  • Mr. Todd Meyers, VP of Bus. Devel. & Marketing

When did Medpace IPO?

(MEDP) raised $150 million in an IPO on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.

Who are Medpace's major shareholders?

Medpace's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Scout Investments Inc. (0.27%), State of Alaska Department of Revenue (0.06%), Crossmark Global Holdings Inc. (0.02%) and We Are One Seven LLC (0.01%). Company insiders that own Medpace stock include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Medpace Limited Partnership and Stephen P Ewald. View Institutional Ownership Trends for Medpace.

Which major investors are selling Medpace stock?

MEDP stock was sold by a variety of institutional investors in the last quarter, including Scout Investments Inc. and Crossmark Global Holdings Inc.. Company insiders that have sold Medpace company stock in the last year include August J Troendle, Jesse J Geiger, Medpace Investors, Llc and Stephen P Ewald. View Insider Buying and Selling for Medpace.

Which major investors are buying Medpace stock?

MEDP stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue and We Are One Seven LLC. View Insider Buying and Selling for Medpace.

How do I buy shares of Medpace?

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Medpace's stock price today?

One share of MEDP stock can currently be purchased for approximately $77.79.

How big of a company is Medpace?

Medpace has a market capitalization of $2.79 billion and generates $704.59 million in revenue each year. The company earns $73.18 million in net income (profit) each year or $2.59 on an earnings per share basis. Medpace employs 2,900 workers across the globe.View Additional Information About Medpace.

What is Medpace's official website?

The official website for Medpace is http://www.medpace.com/.

How can I contact Medpace?

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected]


MarketBeat Community Rating for Medpace (NASDAQ MEDP)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  270 (Vote Outperform)
Underperform Votes:  253 (Vote Underperform)
Total Votes:  523
MarketBeat's community ratings are surveys of what our community members think about Medpace and other stocks. Vote "Outperform" if you believe MEDP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MEDP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/14/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel